BACKGROUND: Vaccination provides long-term immunity to hepatitis A virus (HAV) among the general population, but there are no such data regarding vaccine durability among human immunodeficiency virus (HIV)-infected adults. METHODS: We retrospectively studied HIV-infected adults who had received 2 doses of HAV vaccine. We analyzed blood specimens taken at 1 year, 3 years, and, when available, 6-10 years postvaccination. HAV immunoglobulin G (IgG) values of ≥10 mIU/mL were considered seropositive. RESULTS: We evaluated specimens from 130 HIV-infected adults with a median age of 35 years and a median CD4 cell count of 461 cells/mm(3) at or before time of vaccination. Of these, 49% had an HIV RNA load <1000 copies/mL. Initial vaccine responses were achieved in 89% of HIV-infected adults (95% confidence interval [CI], 83%-94%), compared with 100% (95% CI, 99%-100%) of historical HIV-uninfected adults. Among initial HIV-infected responders with available specimens, 90% (104 of 116; 95% CI, 83%-95%) remained seropositive at 3 years and 85% (63 of 74; 95% CI, 75%-92%) at 6-10 years. Geometric mean concentrations (GMCs) among HIV-infected adults were 154, 111, and 64 mIU/mL at 1, 3, and 6-10 years, respectively, compared with 1734, 687, and 684 mIU/mL among HIV-uninfected persons. Higher GMCs over time among HIV-infected adults were associated with lower log(10) HIV RNA levels (β = -.12, P = .04). CONCLUSIONS: Most adults with well-controlled HIV infections had durable seropositive responses up to 6-10 years after HAV vaccination. Suppressed HIV RNA levels are associated with durable HAV responses.
BACKGROUND: Vaccination provides long-term immunity to hepatitis A virus (HAV) among the general population, but there are no such data regarding vaccine durability among human immunodeficiency virus (HIV)-infected adults. METHODS: We retrospectively studied HIV-infected adults who had received 2 doses of HAV vaccine. We analyzed blood specimens taken at 1 year, 3 years, and, when available, 6-10 years postvaccination. HAV immunoglobulin G (IgG) values of ≥10 mIU/mL were considered seropositive. RESULTS: We evaluated specimens from 130 HIV-infected adults with a median age of 35 years and a median CD4 cell count of 461 cells/mm(3) at or before time of vaccination. Of these, 49% had an HIV RNA load <1000 copies/mL. Initial vaccine responses were achieved in 89% of HIV-infected adults (95% confidence interval [CI], 83%-94%), compared with 100% (95% CI, 99%-100%) of historical HIV-uninfected adults. Among initial HIV-infected responders with available specimens, 90% (104 of 116; 95% CI, 83%-95%) remained seropositive at 3 years and 85% (63 of 74; 95% CI, 75%-92%) at 6-10 years. Geometric mean concentrations (GMCs) among HIV-infected adults were 154, 111, and 64 mIU/mL at 1, 3, and 6-10 years, respectively, compared with 1734, 687, and 684 mIU/mL among HIV-uninfectedpersons. Higher GMCs over time among HIV-infected adults were associated with lower log(10) HIV RNA levels (β = -.12, P = .04). CONCLUSIONS: Most adults with well-controlled HIV infections had durable seropositive responses up to 6-10 years after HAV vaccination. Suppressed HIV RNA levels are associated with durable HAV responses.
Authors: Carol A Kemper; Richard Haubrich; Ian Frank; Gary Dubin; Charles Buscarino; J Allen McCutchan; Stanley C Deresinski Journal: J Infect Dis Date: 2003-03-24 Impact factor: 5.226
Authors: Amy C Weintrob; Greg A Grandits; Brian K Agan; Anuradha Ganesan; Michael L Landrum; Nancy F Crum-Cianflone; Erica N Johnson; Claudia E Ordóñez; Glenn W Wortmann; Vincent C Marconi Journal: J Acquir Immune Defic Syndr Date: 2009-12 Impact factor: 3.731
Authors: P Van Damme; J Banatvala; O Fay; S Iwarson; B McMahon; K Van Herck; D Shouval; P Bonanni; B Connor; G Cooksley; G Leroux-Roels; F Von Sonnenburg Journal: Lancet Date: 2003-09-27 Impact factor: 79.321
Authors: Pierre Alex Crisinel; Klara Maria Posfay-Barbe; Christoph Aebi; Jean-Jacques Cheseaux; Christian Kahlert; Christoph Rudin; David Nadal; Claire-Anne Siegrist Journal: Clin Vaccine Immunol Date: 2012-08-29
Authors: Adriana Weinberg; Amanda A Allshouse; Samantha Mawhinney; Jennifer Canniff; Lorie Benning; Eryka L Wentz; Howard Minkoff; Mary Young; Marek Nowicki; Ruth Greenblatt; Mardge H Cohen; Elizabeth T Golub Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris Journal: MMWR Recomm Rep Date: 2020-07-03
Authors: Aída de Fátima Thomé Barbosa Gouvêa; Maria Isabel de Moraes Pinto; Maristela Miyamoto; Daisy Maria Machado; Silvana Duarte Pessoa; Fabiana Bononi do Carmo; Suênia Cordeiro de Vasconcelos Beltrão; Regina Célia de Menezes Succi Journal: Rev Paul Pediatr Date: 2015-03-28